Nivolumab,Ipilimumab,celecoxib
BMS
['congrat', '/ipi', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'nivo']
#esmo22 99% pathologic response with nivo/ipi in dmmr crc and no disease recurrences!! congrats . nice to see these data for other cancers 
Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine.